Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Leukemia, Myeloid, Chronic-Phase
Interventions
DRUG

Dasatinib + PegIFN

Trial Locations (14)

Unknown

Helsinki University Central Hospital, Helsinki

Bergen University Central Hospital, Bergen

Rikshospitalet, Oslo

Stavanger University Hospital, Stavanger

University Hospital of Northern Norway, Tromsø

St Olavs Hospital - Trondheim University Hospital, Trondheim

Linköping University Hospital, Linköping

Sunderby Sjukhus, Luleå

Lund University Hospital, Lund

Örebro University Hospital, Örebro

Karolinska University Hospital, Stockholm

Sundsvall County Hospital, Sundsvall

Umeå University Hospital, Umeå

Uppsala University Hospital, Uppsala

All Listed Sponsors
lead

Norwegian University of Science and Technology

OTHER

NCT01725204 - Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia | Biotech Hunter | Biotech Hunter